Conference Coverage

Renal denervation for hypertension rebounds


 

REPORTING FROM EUROPCR 2018

In the real RDN group, 24-hour ambulatory blood pressure fell from baseline to 6 months of follow-up to a statistically significant and clinically meaningful degree: by 9.0 mm Hg systolic, compared with 1.6 mm Hg in controls, and by 6.0 mm Hg diastolic versus 1.9 mm Hg with the sham procedure. Similarly, office blood pressure fell by 9.4/5.2 mm Hg with RDN, compared with 2.6/1.7 mm Hg in controls.

Dr. David Kandzari, director of interventional cardiology and chief scientific officer at the Piedmont Heart Institute in Atlanta Bruce Jancin/MDedge News

Dr. David E. Kandzari

Notably, 24-hour ambulatory systolic blood pressure was significantly lower in the RDN group around the clock.

“This may have important considerations with regard to pharmacotherapies with pharmacokinetic peaks and troughs in the early morning hours and late evening, or perhaps for groups with hypertension who are at especially high risk for cardiovascular events, such as those with nocturnal or early morning hypertension,” observed Dr. Kandzari, director of interventional cardiology and chief scientific officer at the Piedmont Heart Institute in Atlanta.

“This raises the concept of an ‘always on’ effect for renal denervation therapy that may be in distinction to pharmacotherapy and independent of adherence issues,” he added.

Pages

Recommended Reading

EAGLES: Smoking cessation therapy did not up cardiovascular risk
MDedge Cardiology
VIDEO: Triple-antihypertensive pill nails early therapy
MDedge Cardiology
MDedge Daily News: Diabetes patients ignore a deadly risk
MDedge Cardiology
Consider spironolactone in treatment-resistant hypertension
MDedge Cardiology
24-hour ambulatory BP measurements strongly predict mortality
MDedge Cardiology
Women’s representation in CV drug trials still lagging
MDedge Cardiology
Nebivolol looks like best beta-blocker for hypertension
MDedge Cardiology
MDedge Daily News: Is ‘medical aid in dying’ suicide?
MDedge Cardiology
New BP guidelines synergize with transformed primary care
MDedge Cardiology
In PAH trials, clinical worsening risk rose with time
MDedge Cardiology